Century Therapeutics (NASDAQ:IPSC – Get Rating) had its target price cut by research analysts at HC Wainwright from $19.00 to $17.00 in a report issued on Friday, The Fly reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 340.41% from the company’s previous close. HC Wainwright also issued estimates for Century Therapeutics’ FY2024 earnings at ($2.70) EPS.
A number of other equities analysts also recently issued reports on IPSC. SVB Leerink dropped their price objective on shares of Century Therapeutics from $20.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, January 6th. EF Hutton Acquisition Co. I restated a “buy” rating and set a $16.00 target price on shares of Century Therapeutics in a research note on Thursday. Chardan Capital began coverage on shares of Century Therapeutics in a research note on Tuesday, December 27th. They set a “buy” rating and a $19.00 target price on the stock. Finally, Piper Sandler decreased their target price on shares of Century Therapeutics from $24.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday, January 6th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $19.00.
Century Therapeutics Stock Performance
IPSC opened at $3.86 on Friday. The company has a current ratio of 13.44, a quick ratio of 13.44 and a debt-to-equity ratio of 0.02. The company has a market cap of $227.62 million, a price-to-earnings ratio of -1.96 and a beta of 0.69. The company’s 50 day moving average is $4.53 and its 200 day moving average is $7.68. Century Therapeutics has a 12-month low of $3.54 and a 12-month high of $14.02.
Institutional Investors Weigh In On Century Therapeutics
Century Therapeutics Company Profile
Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Century Therapeutics (IPSC)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.